Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ARCAGY/ GINECO GROUP
Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer. Patients will receive pyridoxin to prevent cutaneo-mucinous toxicities.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
first metastatic chemo line
presence of measurable or bone lesion
at least one lesion outside the radiated areas
can have previously received hormonotherapy, chemotherapy in adjuvant phase, radiotherapy if older than 4 weeks
You may not be if
only local tumoral progression
symptomatic cerebral metastasis
neuropathy \> NCI-CTC 2
previous cancer within 10 years \_ previous cancer within 10 years
Clareo Health | Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer
